These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35242380)

  • 21. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes and immune phenotypes associated with
    Malhotra J; Ryan B; Patel M; Chan N; Guo Y; Aisner J; Jabbour SK; Pine S
    J Thorac Dis; 2022 Jun; 14(6):1772-1783. PubMed ID: 35813711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib.
    Yu R; Bai H; Li T; Gao B; Han J; Chang G; Zhang P; Fei K; He X; Wang J
    Transl Oncol; 2021 Sep; 14(9):101163. PubMed ID: 34192651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases.
    Stein MK; Pandey M; Xiu J; Tae H; Swensen J; Mittal S; Brenner AJ; Korn WM; Heimberger AB; Martin MG
    JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.
    Hou H; Qin K; Liang Y; Zhang C; Liu D; Jiang H; Liu K; Zhu J; Lv H; Li T; Zhang X
    Cancer Manag Res; 2019; 11():5665-5675. PubMed ID: 31417310
    [No Abstract]   [Full Text] [Related]  

  • 26. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.
    Wang H; Chen S; Meng D; Wu C; Zhu J; Jiang M; Ning J; Wu S; Wu L; Li J; Chen B; Zhao S; Li W; Yu J; Fang Q; Zhu J; Zhao W; He Y; Zhou C
    Onco Targets Ther; 2021; 14():2953-2965. PubMed ID: 33976553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients.
    Peng P; Lv G; Hu J; Wang K; Lv J; Guo G
    Ann Transl Med; 2021 Aug; 9(16):1321. PubMed ID: 34532458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.
    Zhu YJ; Qu X; Zhan DD; Chen HH; Li HP; Liu LR; Chen X; Liu YH; Li Y; Bai JP; Ye S; Zhang HB
    Clin Lung Cancer; 2021 Jan; 22(1):e98-e111. PubMed ID: 33067127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
    Chevallier M; Tsantoulis P; Addeo A; Friedlaender A
    Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant genetic alterations are associated with response to
    Chen H; Liu M; Dai Z; Li S; Luo Y; Wang Y; Su W; Cai W; Yang D; Huang J; Yang Z
    Transl Lung Cancer Res; 2020 Aug; 9(4):1225-1234. PubMed ID: 32953500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
    Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418).
    Mascarenhas E; Gelatti AC; Araújo LH; Baldotto C; Mathias C; Zukin M; Werutsky G; Pacheco P; Gomes R; de Castro G; Cordeiro de Lima VC
    Thorac Cancer; 2021 Mar; 12(5):580-587. PubMed ID: 33314759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
    Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship between different subtypes of
    Yang Y; Shen S; Sun Y; Husain H; Zhou H; Lu S; Li Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):213-223. PubMed ID: 35280306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation Profile of Resected
    Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
    Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic and molecular characteristics of Chinese lung adenocarcinoma patients with
    Wang L; Liu Z; Wan Z; Jiang D; Zhang M; Liu S; Che N
    Ann Transl Med; 2022 Feb; 10(4):220. PubMed ID: 35280421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.